Healthcare -
Drug Manufacturers - General - NASDAQ - FR
$ 50.74
0 %
$ 127 B
Market Cap
27.43
P/E
1. INTRINSIC VALUE
Balance Sheet
Sanofi
| Current Assets | 30.7 B |
| Cash & Short-Term Investments | 8.71 B |
| Receivables | 11 B |
| Other Current Assets | 10.9 B |
| Non-Current Assets | 95.8 B |
| Long-Term Investments | 3.26 B |
| PP&E | 11.8 B |
| Other Non-Current Assets | 80.7 B |
| Current Liabilities | 24.2 B |
| Accounts Payable | 7.33 B |
| Short-Term Debt | 2.32 B |
| Other Current Liabilities | 14.5 B |
| Non-Current Liabilities | 27.9 B |
| Long-Term Debt | 16.1 B |
| Other Non-Current Liabilities | 11.8 B |
EFFICIENCY
Earnings Waterfall
Sanofi
| Revenue | 46 B |
| Cost Of Revenue | 14.2 B |
| Gross Profit | 31.8 B |
| Operating Expenses | 23.9 B |
| Operating Income | 7.88 B |
| Other Expenses | 2.48 B |
| Net Income | 5.4 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sanofi
| Net Income | 5.4 B |
| Depreciation & Amortization | 3.78 B |
| Capital Expenditures | -3.02 B |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 764 M |
| Others | 2.89 B |
| Free Cash Flow | 7.23 B |
Wall Street Analysts Price Targets
Sanofi
Wall Street analysts predict an average 1-year price target for SNY of $59.7 , with forecasts ranging from
a
low of
$55 to a high of $64 .
SNY Lowest Price Target
Wall Street Target
55 USD
8.40%
SNY Average Price Target
Wall Street Target
59.7 USD
17.59%
SNY Highest Price Target
Wall Street Target
64 USD
26.13%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
1.48 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Sanofi
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Sanofi Down 10% in 3 Months: How Should You Play the Stock?
Sanofi's SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past three months after Trump announced the appointment of Robert F.
zacks.com
- 1 week ago
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target specific collaboration and license agreement for the use of their novel and proprietary AntiClastic Antisense Platform with Sanofi for a central nervous system (CNS) target. In return, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5 million.
businesswire.com
- 1 week ago
Gaming stocks likely to outperform semiconductor stocks in 2025
As 2025 draws near, the financial spotlight is moving from semiconductor companies to gaming stocks. Video game companies have been a bright spot for investors amid global unpredictability due to a spike in demand for leisure and gaming advancements.
invezz.com
- 2 weeks ago
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.
zacks.com
- 3 weeks ago
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
globenewswire.com
- 3 weeks ago
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replacing Gilles Schnepp who has decided to leave the Board at the end of 2024.
globenewswire.com
- 1 month ago
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.
zacks.com
- 1 month ago
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?
Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
zacks.com
- 1 month ago
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
U.S.-traded shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY) took off Tuesday after the two drugmakers reported positive results from a study of their treatment for ulcerative colitis (UC) and Crohn's disease.
investopedia.com
- 1 month ago
TD says Spyre has 'superior TL1A program' after Teva data
TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the "impressive results" from Teva (TEVA) and Sanofi (SNY) in inflammatory bowel diseases. Similar to its bigger rivals, Spyre has an anti-TL1A monoclonal antibody in its product pipeline, known as SPY002, the analyst tells investors in a research note. TD believes Spyre has the "superior TL1A program" and its combination treatments under development "will further elevate outcomes." Teva and Sanofi's results "further validate TL1A inhibition as a highly promising mechanism" for both ulcerative colitis and Crohn's disease, contends the firm. Spyre Therapeutics +0.105 (+0.43%) Teva +4.32 (+26.18%) Sanofi +3.38 (+7.37%)
https://thefly.com
- 1 month ago
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
wsj.com
- 1 month ago
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
benzinga.com
- 1 month ago
8. Profile
Summary
Sanofi SNY
COUNTRY
FR
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 127 B
Dividend Yield
0.00%
Description
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Contact
54, Rue La BoEtie, Paris, 75008
https://www.sanofi.com
IPO
Date
July 1, 2002
Employees
86088
Officers
Mr. Dante Beccaria
Global Compliance Officer & Vice President
Ms. Madeleine Roach
Executive Vice President & Head of Business Operations
Dr. Josephine Fubara
Chief Science Officer of Consumer Health Care
Mr. Pierre Chancel
Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
Mr. François-Xavier Roger
Executive Vice President & Chief Financial Officer
Mr. Roy Papatheodorou
Executive Vice President & General Counsel
Mr. Thomas Kudsk Larsen
Head of Investor Relations
Mr. Josep Catlla
Head of Communications
Mr. Laurent Gilhodes
Principal Accounting Officer and Vice President of Corporate Accounting
Mr. Paul Hudson
Chief Executive Officer & Director